KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Operating Expenses (2017 - 2025)

Historic Operating Expenses for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $201.3 million.

  • Amneal Pharmaceuticals' Operating Expenses rose 1186.31% to $201.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $716.9 million, marking a year-over-year increase of 1179.63%. This contributed to the annual value of $669.5 million for FY2024, which is 1245.12% up from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Operating Expenses stood at $201.3 million for Q3 2025, which was up 1186.31% from $173.3 million recorded in Q2 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' Operating Expenses peaked at $201.3 million during Q3 2025, and registered a low of $139.0 million during Q2 2021.
  • Its 5-year average for Operating Expenses is $156.3 million, with a median of $152.7 million in 2024.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Operating Expenses surged by 1964.55% in 2021, and later plummeted by 782.3% in 2022.
  • Quarter analysis of 5 years shows Amneal Pharmaceuticals' Operating Expenses stood at $156.4 million in 2021, then dropped by 7.82% to $144.2 million in 2022, then grew by 7.65% to $155.2 million in 2023, then rose by 18.2% to $183.4 million in 2024, then rose by 9.74% to $201.3 million in 2025.
  • Its Operating Expenses was $201.3 million in Q3 2025, compared to $173.3 million in Q2 2025 and $158.9 million in Q1 2025.